$CRSP News

CRISPR Therapeutics AG (CRSP) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Is CRISPR Therapeutics (CRSP) One Of The Under-The-Radar Stocks With Massive Upside For 2026?

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Assessing CRISPR Therapeutics (CRSP) Valuation After Narrower Q1 2026 Loss And Pipeline Progress

CRISPR Therapeutics AG (CRSP) Reports Q1 2026 Results

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

CRISPR Therapeutics Enters Second Phase As CASGEVY Uptake And Data Build

Bernstein Maintains Market Perform on CRISPR Therapeutics, Raises Price Target to $56

CRISPR Therapeutics AG (CRSP) Presents at Bank of America Global Healthcare Conference 2026 Transcript

1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist?

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $82

Is It Time To Reconsider CRISPR Therapeutics (CRSP) After A 58% One Year Rally?

CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference

Crispr Therapeutics Q1 Earnings: Casgevy Growth, H2 In-Vivo Catalysts Make Buy Case

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

CRISPR Therapeutics AG (CRSP) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

A Turning Point For Crispr Therapeutics As Commercial Growth Accelerates

Piper Sandler Reiterates Overweight on CRISPR Therapeutics, Raises Price Target to $110

CRISPR Therapeutics Prices Upsized $550M Convertible Senior Notes Offering Due 2031 With Option For Additional $50M, Expected To Close March 16, 2026